Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Free Cash Flow (2016 - 2025)

Lipocine's Free Cash Flow history spans 13 years, with the latest figure at -$3.0 million for Q3 2025.

  • For Q3 2025, Free Cash Flow fell 5.39% year-over-year to -$3.0 million; the TTM value through Sep 2025 reached -$5.1 million, down 3.93%, while the annual FY2024 figure was -$1.3 million, 88.96% up from the prior year.
  • Free Cash Flow reached -$3.0 million in Q3 2025 per LPCN's latest filing, down from -$1.9 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $9.0 million in Q4 2021 to a low of -$7.0 million in Q3 2021.
  • Average Free Cash Flow over 5 years is -$1.9 million, with a median of -$2.6 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: skyrocketed 344.15% in 2021, then plummeted 181.8% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at $9.0 million in 2021, then crashed by 121.52% to -$1.9 million in 2022, then fell by 4.95% to -$2.0 million in 2023, then surged by 183.28% to $1.7 million in 2024, then plummeted by 276.47% to -$3.0 million in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Free Cash Flow are -$3.0 million (Q3 2025), -$1.9 million (Q2 2025), and -$2.0 million (Q1 2025).